Hemostemix Inc (CVE:HEM) shares traded up 40% during mid-day trading on Wednesday . The company traded as high as C$0.04 and last traded at C$0.04, 98,100 shares were traded during trading. An increase of 20% from the average session volume of 81,762 shares. The stock had previously closed at C$0.03.

The firm has a market capitalization of $7.52 million and a P/E ratio of -1.67. The business has a 50-day moving average price of C$0.03 and a 200-day moving average price of C$0.05.

Hemostemix Company Profile (CVE:HEM)

Hemostemix Inc, a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia.

Further Reading: Straddles

Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.